AABB Releases New Educational Videos on CCP
April 06, 2021
To help health care professionals better understand the appropriate use and efficacy of COVID-19 convalescent plasma (CCP) as a treatment option for patients with COVID-19, AABB convened a panel of experts in the field to review the science and generate evidence-based interim recommendations. The recommendations were released in February
and are consistent with the FDA’s guidance to administer only high-titer units of CCP early in the course of the disease.
This week, AABB released two new videos, titled “Convalescent Plasma: Recommendations for Physicians Treating Patients With COVID-19
,” to accompany the recent recommendations. The videos are designed to provide further insight to clinicians across various subspecialties about the effective and appropriate use of CCP, as well as about the evolving state of research on this critical topic. AABB’s Chief Medical Officer Claudia S. Cohn, MD, PhD, moderates the videos, which were developed by AABB with support by a grant from The Fight is in Us Coalition
. “This program is intended to help physicians identify the subset of COVID-19 patients who are most likely to benefit from treatment with CCP,” Cohn said.
In the first video, “Overview and Safety,” Shmuel Shoham, MD, associate professor of medicine at Johns Hopkins University School of Medicine, provides an overview of CCP and outlines safety considerations. The second video, “CCP Efficacy: Timing and Titer,” featuring Christian Merlo, MD, MPH, associate professor of medicine and epidemiology at Johns Hopkins University School of Medicine, provides information on the efficacy of CCP, with an emphasis on early administration of high-titer units.